GleamWall
中文EN

GRML Greenland Mines Ltd

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1907223 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-199.9%
TTM EPS YoY109.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-44.3%
ROA-44.0%
ROIC (approx.)-56.3%
Asset turnover—

Leverage & solvency

Liabilities / assets1.0%
Debt / equity0.00x
Current ratio62.16x
Interest coverage25.06x

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$634,187$0
SG&A expense$3.08M$2.78M
Operating income-$7.15M-$5.54M
Interest expense$2.31M$356,603
Pretax income-$10.55M-$6.15M
Net income-$10.55M-$6.15M
EPS (basic)-0.22-0.32
EPS (diluted)-0.22-0.32
Weighted avg. shares (diluted)48.49M19.25M
Balance sheet
Cash & equivalents$7.18M$63,741
Current assets$7.29M$157,811
PP&E, net$0—
Intangibles$2.30M—
Total assets$9.59M$2.46M
Current liabilities$76,764$1.25M
Total liabilities$129,764$1.27M
Shareholders' equity$9.46M$1.19M
Shares outstanding1.48M27.08M
Cash flow statement
Operating cash flow-$5.89M-$2.95M
Investing cash flow—-$123,497
Financing cash flow$13.00M$3.13M
Stock-based compensation$1.57M$2.65M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.